Get your startup to the next level

The Merck Accelerator is looking for startups with the potential to reshape entire industries and make people's lives richer. The focus is on startups in the fields of healthcare, life science and performance materials - with a digital perspective. Do you have plans to internationalize your business? Are you ready to get your start-up to the next level?

The Merck Accelerator is looking for true innovators and entrepreneurs with a start-up mindset. Candidates applying to the accelerator program should be startups in the fields of healthcare, life science and performance materials who are dedicated to the program and ready to give their all for the entire program period.

Merck Accelerator Spring 2017 Application is now Open!

  • You are: A startup in the fields of Healthcare, Life Science and Performance Materials
  • Application: October 17, 2016 - December 19, 2016
  • Announcement: February 15, 2017
  • Program duration: March 6, 2017 - May 24, 2017

Here are the key benefits ready for you:
1. Financial support up to €50,000 for your team.
2. Accommodation & office space in the center of Darmstadt, Germany.
3. Access to a global network with 50,000+ industry leaders and investors.
4. Deep-dive mentoring sessions to bring your startup to the next level.
5. Travel & conference opportunities to enrich your international experience as well as the possibility to expand your network through our Silicon Valley extension program.

Here's the process:
1. Check the Merck Accelerator program, discover if we are the perfect fit for your startup.
2. Choose the location that you want to be part of.
3. Complete and submit the Darmstadt, Germany application form or Nairobi, Kenya application form by December 19, 2016.
4. After careful consideration of all aspects of each startup, the program participants will be chosen. You will get results by February 15, 2017. 5. Prepare to innovate, and change the world!

For further information, please visit:
http://accelerator.merckgroup.com

About Merck
Merck is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop technologies that improve and enhance life - from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. In 2015, Merck generated sales of € 12.85 billion in 66 countries.

Founded in 1668, Merck is the world's oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. Merck, Darmstadt, Germany holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.

Most Popular Now

Pfizer's elranatamab granted FDA Breakthrough Ther…

Pfizer Inc. (NYSE:PFE) announced its investigational cancer immunotherapy, elranatamab, received Breakthrough Therapy Designation from the U.S. Food and Drug Administrati...

Salvat Laboratories announces submission of New Dr…

Salvat Laboratories announced that it has submitted a New Drug Application (NDA) to the FDA for the approval of the first ocular corticosteroid formulated in a nanoemulsi...

Bayer with continued strong performance

The Bayer Group maintained its strong business performance across all three divisions in the third quarter. "Despite rising inflation and global supply chain problems, we...

Vividion Therapeutics names Jenna Goldberg as Chie…

Vividion Therapeutics, Inc., a biopharmaceutical company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision the...

New insights on antibody responses to Omicron vari…

Knowing how well vaccination against one SARS-CoV-2 strain (with or without previous infection) counteracts infection with a different strain is a critical research quest...

Pfizer and BioNTech receive positive CHMP opinion …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a booster dose of their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine (COMIRNATY® Original/Omicron ...

Sugar molecules as a target in cancer therapy

Cancer cells use sugar molecules on their surface to disable attacks by the body's immune system. Researchers at the University of Basel now report on how this mechanism ...

COVID vaccination improves effectiveness of cancer…

Patients with nasopharyngeal cancer are often treated with drugs that activate their immune system against the tumor. Until now, it was feared that vaccination against Co...

Making melanoma immortal: Pitt scientists discover…

Scientists at the University of Pittsburgh School of Medicine have discovered the missing puzzle piece in the mystery of how melanoma tumors control their mortality. I...

New drug shows promise for fighting both COVID-19 …

While vaccination can provide life-saving protection against COVID-19, scientists are still searching for ways to treat severe infections, including in people who cannot ...

Study reveals vaccine confidence declined consider…

A new study suggests that, despite the success of the COVID-19 vaccination campaigns, vaccine confidence has declined significantly since the start of the pandemic. Re...

Sanofi and GSK's next-generation COVID-19 booster …

After the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for VidPrevtyn® Beta, the vaccine was approved by t...